No abstract

We present a noncontact method to monitor blood oxygen saturation (SpO2). The method uses a CMOS camera with a trigger control to allow recording of photoplethysmography (PPG) signals alternatively at two particular wavelengths, and determines the SpO2 from the measured ratios of the pulsatile to the nonpulsatile components of the PPG signals at these wavelengths. The signal-to-noise ratio (SNR) of the SpO2 value depends on the choice of the wavelengths. We found that the combination of orange (λ = 611 nm) and near infrared (λ = 880 nm) provides the best SNR for the noncontact video-based detection method. This combination is different from that used in traditional contact-based SpO 2 measurement since the PPG signal strengths and camera quantum efficiencies at these wavelengths are more amenable to SpO2 measurement using a noncontact method. We also conducted a small pilot study to validate the noncontact method over an SpO2 range of 83%-98%. This study results are consistent with those measured using a reference contact SpO2 device ( r = 0.936, ). The presented method is particularly suitable for tracking one's health and wellness at home under free-living conditions, and for those who cannot use traditional contact-based PPG devices.

Background The Delta and Omicron variants of SARS-CoV-2 are currently responsible for breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612, a multitope subunit vaccine containing S1-RBD-sFc protein and rationally designed promiscuous peptides representing sarbecovirus conserved helper T cell and cytotoxic T lymphocyte epitopes on the nucleocapsid (N), membrane (M), and spike (S2) proteins. Method We conducted a phase I primary 2-dose (28 days apart) trial of 10, 30, or 100 μg UB-612 in 60 healthy young adults 20 to 55 years old, and 50 of them were boosted with 100 μg of UB-612 approximately 7 to 9 months after the second dose. A separate placebo-controlled and randomized phase II study was conducted with 2 doses of 100 μg of UB-612 ( n = 3,875, 18–85 years old). We evaluated interim safety and immunogenicity of phase I until 14 days after the third (booster) dose and of phase II until 28 days after the second dose. Results No vaccine-related serious adverse events were recorded. The most common solicited adverse events were injection site pain and fatigue, mostly mild and transient. In both trials, UB-612 elicited respective neutralizing antibody titers similar to a panel of human convalescent sera. The most striking findings were long-lasting virus-neutralizing antibodies and broad T cell immunity against SARS-CoV-2 variants of concern (VoCs), including Delta and Omicron, and a strong booster-recalled memory immunity with high cross-reactive neutralizing titers against the Delta and Omicron VoCs. Conclusion UB-612 has presented a favorable safety profile, potent booster effect against VoCs, and long-lasting B and broad T cell immunity that warrants further development for both primary immunization and heterologous boosting of other COVID-19 vaccines. Trial Registration ClinicalTrials.gov: NCT04545749, NCT04773067, and NCT04967742. Funding UBI Asia, Vaxxinity Inc., and Taiwan Centers for Disease Control, Ministry of Health and Welfare.

We present optical imaging-based methods to measure vital physiological signals, including breathing frequency (BF), exhalation flow rate, heart rate (HR), and pulse transit time (PTT). The breathing pattern tracking was based on the detection of body movement associated with breathing using a differential signal processing approach. A motion-tracking algorithm was implemented to correct random body movements that were unrelated to breathing. The heartbeat pattern was obtained from the color change in selected region of interest (ROI) near the subject's mouth, and the PTT was determined by analyzing pulse patterns at different body parts of the subject. The measured BF, exhaled volume flow rate and HR are consistent with those measured simultaneously with reference technologies (r = 0.98, for HR; r = 0.93, for breathing rate), and the measured PTT difference (30-40 ms between mouth and palm) is comparable to the results obtained with other techniques in the literature. The imaging-based methods are suitable for tracking vital physiological parameters under free-living condition and this is the first demonstration of using noncontact method to obtain PTT difference and exhalation flow rate.

Proton magnetic resonance spectroscopy (1H-MRS) is capable of noninvasively detecting metabolic changes that occur in the brain tissue in vivo. Its clinical utility has been limited so far, however, by analytic methods that focus on independently evaluated metabolites and require prior knowledge about which metabolites to examine. Here, we applied advanced computational methodologies from the field of metabolomics, specifically partial least squares discriminant analysis and orthogonal partial least squares, to in vivo 1H-MRS from frontal lobe white matter of 27 patients with relapsing–remitting multiple sclerosis (RRMS) and 14 healthy controls. We chose RRMS, a chronic demyelinating disorder of the central nervous system, because its complex pathology and variable disease course make the need for reliable biomarkers of disease progression more pressing. We show that in vivo MRS data, when analyzed by multivariate statistical methods, can provide reliable, distinct profiles of MRS-detectable metabolites in different patient populations. Specifically, we find that brain tissue in RRMS patients deviates significantly in its metabolic profile from that of healthy controls, even though it appears normal by standard MRI techniques. We also identify, using statistical means, the metabolic signatures of certain clinical features common in RRMS, such as disability score, cognitive impairments, and response to stress. This approach to human in vivo MRS data should promote understanding of the specific metabolic changes accompanying disease pathogenesis, and could provide biomarkers of disease progression that would be useful in clinical trials.